Potential therapeutic targets for Parkinson's disease

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 4, 2008, Pages 425-436

  Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5 hydroxytryptamine; Adenosine receptors; Animal models; Apoptosis; Biomarkers; Dementia; Dopamine; Dyskinesias; Excitatory amino acids; Gene therapy; Glutamic acid decarboxylase; Kinase; Mitochondria; Neuroprotection; Neurotrophins; Parkinson's; Protein aggregation; Ubiquitin proteasome system

Indexed keywords

ADENOVIRUS VECTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA SYNUCLEIN; AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CLONAZEPAM; DOPAMINE; DOPAMINE 1 RECEPTOR; GABAPENTIN; LEVODOPA; MEMBRANE ASSOCIATED GUANYLATE CYCLASE KINASE; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PARKIN; PLACEBO; RASAGILINE; SARIZOTAN; SELEGILINE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TYROSINE 3 MONOOXYGENASE; UBIDECARENONE; UBIQUITIN PROTEIN LIGASE; UNINDEXED DRUG; ANTIPARKINSON AGENT; PHARMACOLOGICAL BIOMARKER; UNCLASSIFIED DRUG;

BALANCE DISORDER; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; GENE OVEREXPRESSION; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTURAL INSTABILITY; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SLEEP DISORDER; SPEECH DISORDER; VIRAL GENE THERAPY; ANIMAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENE THERAPY; METABOLISM;

ANIMALS; ANTIPARKINSON AGENTS; BIOMARKERS, PHARMACOLOGICAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE THERAPY; HUMANS; PARKINSON DISEASE;

EID: 42149138095     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.4.425     Document Type: Review

References (130)

1. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-6
2. Rascol O, Brooks DJ, Korczyn AD, et al. 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91
3. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64:1089-96
4. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508
5. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61
6. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101
7. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6
8. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71
9. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-7
10. De Letter M, Santens P, Estercam I, et al. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners. Clin Linguist Phon 2007;21:783-91
11. De Letter M, Santens P, De Bodt M, et al. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. Clin Neurol Neurosurg 2007;109:495-500
12. Pinto S, Gentil M, Krack P, et al. Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech. Mov Disord 2005;20:1507-15
13. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005;128:2240-9
14. Pinto S, Thobois S, Costes N, et al. Subthalamic nucleus stimulation and dysarthria in Parkinson's disease: a PET study. Brain 2004;127:602-15
15. Ramig LO, Fox C, Sapir S. Parkinson's disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment. Semin Speech Lang 2004;25:169-80
16. Sapir S, Spielman JL, Ramig LO, et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Lang Hear Res 2007;50:899-912
17. Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. Neuroreport 2005;16:1883-7
18. Stefani A, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 2007;130:1596-607
19. Hamani C, Richter E, Schwalb JM, Lozano AM. Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. Neurosurgery 2005;56:1313-21
20. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007
21. Gilman S, Koeppe RA, Chervin RD, et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 2003;61:29-34
22. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000;55:870-1
23. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-92
24. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994;5:747-9
25. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-8
26. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
27. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-54
28. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006;6:1403-11
29. Morgan JC, Sethi KD. Rotigotine for the treatment of Parkinson's disease. Expert Rev Neurother 2006;6:1275-82
30. Schwarzschild MA, Agnati L, Fuxe K, et al. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006;29:647-54
31. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-6
32. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist is tradefylline in advanced PD. Neurology 2003;61:297-303
33. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-7
34. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-13
35. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143
36. Oh JD, Russell DS, Vaughan CL, Chase TN. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 1998;813:150-9
37. Chase TN. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 2004;10:305-13
38. Wessell RH, Ahmed SM, Menniti FS, et al. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 2004;47:184-94
39. Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94:3363-7
40. Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999;6:461-74
41. Doucet J-P, Nakabeppu Y, Bedard PJ, et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of FosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 1997;8:365-81
42. Engber TM, Susel Z, Kua S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-8
43. Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000;47:S70-8
44. Calon F, Birdi S, Rajput AH, et al. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesia. J Neuropathol Exp Neurol 2002;61:186-96
45. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694-706
46. Van Kampen JM, Stoessl AJ. Effects of oligonucleotide antisense to dopamine D1A receptor mRNA in a rodent model of levodopa-induced dyskinesia. Neuroscience 2000;98:61-7
47. Van Kampen JM, Stoessl AJ. Effects of oligonucleotide antisense to dopamine D(3) receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 2003;116:307-14
48. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-7
49. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27:58-62
50. Goetz CC, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179-86
51. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008: published online 3 January 2008, doi:10.1002/mds.21897
52. Iravani MM, Jackson MJ, Kuoppamaki M, et al. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 2003;23:9107-15
53. Meco G, Fabrizio E, Di Rezze S, et al. Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 2003;26:179-81
54. Hallett PJ, Dunah AW, Ravenscroft P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005;48:503-16
55. Fiorentini C, Rizzetti MC, Busi C, et al. Loss of synaptic D1 dopamine/ N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol 2006;69:805-12
56. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6:501-6
57. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-6
58. Morissette M, Dridi M, Calon F, et al. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 2006;21:9-17
59. Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 2006;26:2914-22
60. Zhang J, Vinuela A, Neely MH, et al. Inhibition of the dopamine D1 receptor signaling by PSD-95. J Biol Chem 2007;282:15778-89
61. Mela F, Marti M, Dekundy A, et al. Antagonism of metabotropic glutamate receptor type 5 attenuates 1-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007;101:483-97
62. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7
63. Periquet M, Fulga T, Myllykangas L, et al. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007;27:3338-46
64. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004;3:496-503
65. El Agnaf OM, Paleologou KE, Greer B, et al. A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004; 18:1315-7
66. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007;317:516-9
67. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7
68. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600
69. Smith WW, Pei Z, Jiang H, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9:1231-3
70. Farrer MJ. Lrrk2 in the limelight! Neurology 2007;69:1732-3
71. Shimura H, Hattori N, Kubo SI, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5
72. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-62
73. Bove J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006;60:260-4
74. Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006;60:264-8
75. Manning-Bog AB, Reaney SH, Chou VP, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 2006;60:256-60
76. Mathur BN, Neely MD, Dyllick-Brenzinger M, et al. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res 2007;1168:83-9
77. Fallon L, Belanger CM, Corera AT, et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 2006;8:834-42
78. Dedmon MM, Christodoulou J, Wilson MR, Dobson CM. Heat shock protein 70 inhibits α-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem 2005;280:14733-40
79. Nagel F, Falkenburger BH, Tonges L, et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 2008
80. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 2005;280:2873-8
81. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005;6:11-22
82. Luo GR, Chen S, Le WD. Are heat shock proteins therapeutic target for Parkinson's disease? Int J Biol Sci 2007;3:20-6
83. Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 2006;273:1331-49
84. Rochet JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med 2007;9:1-34
85. Pridgeon JW, Olzmann JA, Chin LS, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007;5:e172. Published online 19 June 2007, doi:10.1371/ journal.pbio.0050172
86. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006;441:1162-6
87. Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006;441:1157-61
88. Shendelman S, Jonason A, Martinat C, et al. DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol 2004;2:e362. Published online 5 October 2004, doi:10.1371/ journal.pbio.0020362
89. Zhou W, Zhu M, Wilson MA, et al. The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein. J Mol Biol 2006; 356:1036-48
90. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83
91. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-43
92. Olanow CW, Schapira AH, LeWitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5:1013-20
93. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-90
94. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50
95. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-71
96. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-6
97. Rascol O, Olanow W, Brooks D, et al. Effect of riluzole on Parkinson's disease progression: a double-blind placebo-controlled study [abstract]. Neurology 2003;60:A288
98. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996;8:1408-14
99. Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005;76:1217-21
100. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl 1):S3-7
101. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-64
102. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007;69:1836-42
103. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73
104. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-95
105. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-66
106. Marks WJ, Ostrem JL, Verhagen L et al. A Phase I, open-label study of CERE-120 (adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]) to assess the safety and tolerability of intraputaminal delivery to subjects with idiopathic Parkinson's disease. Lancet Neurol 2008 (In Press).
107. Ribeiro MJ, Stoessl AJ, Brooks DJ, et al. Effect of a potential neurotrophic drug on the progression of dopaminergic nigrostriatal lesions assessed by 18F-Dopa PET imaging in Parkinson s disease [abstract]. Neurology 2008 In press
108. Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2005;2:129-38
109. Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006;14:564-70
110. Kordower JH, Herzog CD, Dass B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006;60:706-15
111. Lo BC, Schneider BL, Bauer M, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci USA 2004;101:17510-5
112. Mochizuki H, Yamada M, Mizuno Y. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Parkinsonism Relat Disord 2006;12(Suppl 2):S107-9
113. Hashimoto M, Rockenstein E, Mante M, et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model. Gene Ther 2004;11:1713-23
114. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-105
115. Feigin A, Kaplitt MG, Tang C, et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 2007
116. Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002;298:425-9
117. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503
118. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184(Suppl 1):S68-79
119. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-15
120. Quik M, Cox H, Parameswaran N, et al. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62(6):588-96
121. Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007;318:1309-12
122. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908
123. de la Fuente-Fernandez R, Ruth TJ, Sossi V, et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-6
124. de la Fuente-Fernandez R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-6
125. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 2004;56:67-71
126. Lidstone SC, de la Fuente-Fernandez R, Stoessl AJ. The placebo response as a reward mechanism. Semin Pain Med 2005;3:37-42
127. Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002;17:283-8
128. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004;61:412-20
129. Benedetti F, Colloca L, Torre E, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 2004;7:587-8
130. Pollo A, Torre E, Lopiano L, et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 2002;13:1383-6